William N. Kelly

934 total citations
47 papers, 671 citations indexed

About

William N. Kelly is a scholar working on Geriatrics and Gerontology, Pediatrics, Perinatology and Child Health and Toxicology. According to data from OpenAlex, William N. Kelly has authored 47 papers receiving a total of 671 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Geriatrics and Gerontology, 17 papers in Pediatrics, Perinatology and Child Health and 10 papers in Toxicology. Recurrent topics in William N. Kelly's work include Pharmaceutical Practices and Patient Outcomes (28 papers), Pharmaceutical studies and practices (16 papers) and Pharmacovigilance and Adverse Drug Reactions (10 papers). William N. Kelly is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (28 papers), Pharmaceutical studies and practices (16 papers) and Pharmacovigilance and Adverse Drug Reactions (10 papers). William N. Kelly collaborates with scholars based in United States, France and Sweden. William N. Kelly's co-authors include Martin B Van Der Weyden, Douglas E. Miller, T. Donald Rucker, Ulf Bergman, Félix Arellano, Robert P. Wise, Joanne Barnes, Judith K. Jones, William G. Troutman and Frank G. Williams and has published in prestigious journals such as Journal of Biological Chemistry, Clinical Pharmacology & Therapeutics and Drug Safety.

In The Last Decade

William N. Kelly

43 papers receiving 618 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William N. Kelly United States	13	274	168	156	140	82	47	671
Randy C. Hatton United States	18	439 1.6×	176 1.0×	258 1.7×	242 1.7×	65 0.8×	46	1.1k
Lisa E. Hines United States	13	471 1.7×	133 0.8×	72 0.5×	150 1.1×	102 1.2×	40	824
Stephan Kr henb hl Switzerland	11	504 1.8×	155 0.9×	217 1.4×	180 1.3×	122 1.5×	11	927
Allen Brinker United States	16	177 0.6×	91 0.5×	188 1.2×	117 0.8×	51 0.6×	41	1.2k
Katherine Simons Netherlands	4	244 0.9×	146 0.9×	212 1.4×	111 0.8×	67 0.8×	6	517
Serena Slavenburg Netherlands	6	330 1.2×	149 0.9×	85 0.5×	114 0.8×	96 1.2×	12	584
Manfred Criegee‐Rieck Germany	14	343 1.3×	317 1.9×	118 0.8×	375 2.7×	107 1.3×	18	738
Emma Davies United Kingdom	13	458 1.7×	440 2.6×	127 0.8×	342 2.4×	132 1.6×	22	1.1k
Mark S. Horng United States	5	562 2.1×	53 0.3×	245 1.6×	140 1.0×	99 1.2×	7	826
Katja M. Hakkarainen Sweden	12	458 1.7×	261 1.6×	94 0.6×	210 1.5×	167 2.0×	25	745

Countries citing papers authored by William N. Kelly

Since Specialization

Citations

This map shows the geographic impact of William N. Kelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William N. Kelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William N. Kelly more than expected).

Fields of papers citing papers by William N. Kelly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William N. Kelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William N. Kelly. The network helps show where William N. Kelly may publish in the future.

Co-authorship network of co-authors of William N. Kelly

This figure shows the co-authorship network connecting the top 25 collaborators of William N. Kelly. A scholar is included among the top collaborators of William N. Kelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William N. Kelly. William N. Kelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kelly, William N.. (2018). Pharmacy.

Kelly, William N. & William N. Kelly. (2011). Pharmacy. 1 indexed citations

Belknap, Steven M., et al.. (2010). Quality of Methods for Assessing and Reporting Serious Adverse Events in Clinical Trials of Cancer Drugs. Clinical Pharmacology & Therapeutics. 88(2). 231–236. 15 indexed citations

Kelly, William N., Félix Arellano, Joanne Barnes, et al.. (2007). Guidelines for Submitting Adverse Event Reports for Publication. Drug Safety. 30(5). 367–373. 89 indexed citations

Kelly, William N., Félix Arellano, Joanne Barnes, et al.. (2007). Guidelines for submitting adverse event reports for publication. Pharmacoepidemiology and Drug Safety. 16(5). 581–587. 64 indexed citations

Kelly, William N.. (2002). Pharmacy: What It Is and How It Works. Medical Entomology and Zoology. 12 indexed citations

Kelly, William N.. (2001). Potential risks and prevention, part 2: Drug-induced permanent disabilities. American Journal of Health-System Pharmacy. 58(14). 1325–1329. 31 indexed citations

Kelly, William N.. (2001). Potential risks and prevention, Part 4: Reports of significant adverse drug events. American Journal of Health-System Pharmacy. 58(15). 1406–1412. 46 indexed citations

Kelly, William N., et al.. (2001). Potential risks and prevention, part 3: Drug-induced threats to life. American Journal of Health-System Pharmacy. 58(15). 1399–1405. 19 indexed citations

10.

Kelly, William N.. (2001). Can the Frequency and Risks of Fatal Adverse Drug Events Be Determined?. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 21(5). 521–527. 17 indexed citations

11.

Kelly, William N., et al.. (2000). Development of a Nontraditional PharmD Program Offered Jointly Between a Private and Public University. American Journal of Pharmaceutical Education. 64(1). 59–61.

12.

O’Donnell, James S., et al.. (2000). Propylene Glycol Toxicity in a Pediatric Patient: The Dangers of Diluents. Journal of Pharmacy Practice. 13(3). 214–225. 8 indexed citations

13.

Kelly, William N. & T. Donald Rucker. (1994). Considerations in Deciding Which Drugs Should Be in a Formulary. Journal of Pharmacy Practice. 7(2). 51–57. 1 indexed citations

14.

Kelly, William N., et al.. (1992). Pharmacist's responsibility for providing drug information to be used for questionable purposes. American Journal of Health-System Pharmacy. 49(7). 1725–1730.

15.

Meyer, John D., et al.. (1989). Clinical career ladders: Hamot Medical Center.. PubMed. 46(11). 2268–71. 6 indexed citations

16.

Anderson, Roger W., et al.. (1986). Strategic planning for clinical services: Panel discussion. American Journal of Health-System Pharmacy. 43(9). 2174–2177. 3 indexed citations

17.

Chase, Kayla A., et al.. (1984). Total formulary review--the easy way.. PubMed. 19(3). 159–62. 5 indexed citations

18.

Berg, Mary J., et al.. (1980). Erythrocyte Lithium and the Erythrocyte: Plasma Lithium Ratio as Indicators of Mood Changes: Preliminary Report. Drug Intelligence & Clinical Pharmacy. 14(12). 836–841. 1 indexed citations

19.

Kelly, William N., et al.. (1977). Drug Information Centers: Lack of Generic Equivalence. Drug Intelligence & Clinical Pharmacy. 11(12). 728–735. 9 indexed citations

20.

Kelly, William N. & Rodney D. Ice. (1973). Pharmaceutical quality of technetium-99m sulfur colloid. American Journal of Health-System Pharmacy. 30(9). 817–823. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact